以太坊暴跌之下,40 亿抛压在路上!杰克逊霍尔会议将成 “生死劫”?

MarsBitPublished on 2025-08-19Last updated on 2026-08-21

Abstract

40亿美元质押解锁与杰克逊霍尔会议构成双重时空裂缝,而裂缝深处,以太坊正经历从投机燃料向机构资产的痛苦蜕变。

杰克逊霍尔


以太坊价格在八月的烈阳下骤然降温,CoinGecko数据显示,这个市值第二的加密货币已从周内4350美元高点暴跌4.5%,跌穿4150美元支撑位,最低跌至4060美金,创下近两周最低点。这场抛售风暴并非孤立事件——比特币同步回落至113,000美元关口,整个加密市场在美联储政策迷雾中剧烈摇摆。


质押堰塞湖:40亿美元解锁倒计时


以太坊权益证明网络的深处,一场规模空前的资本迁徙正在酝酿。

杰克逊霍尔


链上数据显示,当前验证者退出队列高达910,461枚ETH,按市价计算相当于39.1亿美元的巨额筹码正等待释放。更值得警惕的是,新增质押需求仅258,951枚ETH(约10.9亿美元),净潜在抛压达65.1万枚ETH,形成近30亿美元的资金缺口。


这场资本洪峰的成因暗藏市场结构的深刻变化:

  • ​​杠杆策略崩塌​​:Aave平台上以太坊借贷利率飙升至6%,远高于4%的质押收益,导致循环质押策略(借ETH→质押→再借)彻底崩溃。投资者被迫解除质押偿还贷款,引发“赎回→抛售→价格下跌→更多清算”的死亡螺旋
  • ​​机构风向转变​​:中心化质押平台正迅速蚕食去中心化协议的市场份额。Binance、Coinbase等具备KYC流程和节点故障担责机制的机构,单月吸引超26万枚ETH流入,而Lido市占率跌至24.4%。这种迁移背后是机构对合规性与确定性的极致追求
  • ​​获利了结潮​​:随着以太坊价格逼近2021年历史高点4800美元,早期质押者浮盈超过223%。HashKey Capital流动基金合伙人徐翰指出:“创纪录的退出队列主要由获利了结驱动,参与者希望锁定收益”

尽管以太坊开发人员Preston Van Loon强调退出队列机制可防止验证者大规模外流,维护网络安全,但无法改变40亿美元潜在抛压终将冲击市场的现实。每日约2.4万枚ETH(1.86亿美元)的解锁量,将持续15天考验市场承载力。

宏观风暴眼:杰克逊霍尔前的全球博弈


加密货币市场的震荡恰逢全球资本市场的敏感时刻。​​美联储政策预期的戏剧性转向​​成为关键变量:美国7月生产者价格指数(PPI)同比飙升3.3%,远超预期的2.5%,瞬间将市场对9月美联储降息的预期从98%打压至84%。美债收益率应声反弹,风险资产吸引力急剧衰减。

​​三大宏观利刃同时悬顶​​:

  1. ​​政策预期迷雾​​:杰克逊霍尔全球央行年会召开在即,美联储主席鲍威尔即将发表的主题演讲成为市场风向标。Presto Research研究主管Peter Chung警告:“若鲍威尔言论不及鸽派预期,市场可能出现大幅回调”
  2. ​​财政政策变局​​:美国财政部长贝森特明确排除用国债收益配置比特币的计划,击碎“主权资金入场”的市场幻想。虽几小时后其在社交平台软化立场,称将探索“预算中性”路径增持比特币,但政策不确定性已然发酵
  3. ​​地缘风险升温​​:Wintermute场外交易员Jake Ostrovskis在社交媒体透露,交易员正为特朗普可能在杰克逊霍尔发表的“强硬讲话”提前部署风险对冲。这种“已知的未知”加剧资本避险情绪

杰克逊霍尔

市场流动性指标已亮起黄灯。加密货币全网合约过去24小时爆仓3.32亿美元,超10万投资者惨遭清洗,其中多单爆仓占比高达71%。这种杠杆出清与2020年3月流动性危机(比特币两日跌40%)及2022年FTX崩盘(比特币暴跌55%)时的市场结构惊人相似。

链上寒冬:生态活性崩塌与ETF失血


以太坊网络的底层活力正以惊人速度消退。​​链上关键指标全线飘红​​:

  • 每日活跃地址从84.1万骤降至60万,跌幅达28%
  • 新增地址数量同步萎缩28%,从19.2万跌至13.8万
  • DeFi锁仓量单周锐减37亿美元,揭示“需求萎缩→收益下降→质押逃离”的恶性循环

杰克逊霍尔

更令人忧心的是​​机构资金风向转变​​。以太坊ETF在经历创纪录的单周28.5亿美元净流入后,于8月19日突然出现1.966亿美元单日净流出,这是该产品上市以来的第二大资金出逃。贝莱德的ETHA虽累计吸引121.6亿美元资金,但周一流出量占比高达18%,显示机构短期撤退迹象。


这种资金流动逆转与比特币ETF呈现镜像效应:灰度、方舟投资的比特币ETF遭遇资金外流,而贝莱德的IBIT仍保持净流入。BTCMarkets分析师Rachael Lucas解读道:“这更多是资本轮动而非信心崩溃,投资者正将资金整合至成本更低的产品”。

比特币联动:机构棋局与市场信号


比特币的走势为观察以太坊提供了关键锚点。全球最大加密货币从124,350美元历史高点回落7.5%,技术面呈现“台阶式”下探特征。这种回调与MicroStrategy(MSTR)股价跌至四个月低点形成共振——该公司宣布放宽股票增发限制,允许在股价低于净资产价值2.5倍时“策略性发行股票”。


​​市场裂变中的关键信号​​:

  • ​​衍生品预警​​:比特币在创出新高后两度受阻,大量杠杆多头被自动平仓。CME以太坊期货净持仓数据显示,对冲基金驱动的以太坊空头头寸从8月5日的23亿美元暴增至41.9亿美元,近乎翻倍
  • ​​周期定位​​:HashKey Group首席分析师丁肇飞指出,本轮下跌更符合“上涨趋势中的正常回撤”,以去杠杆为主导,区别于由宏观环境和行业重大事件驱动的趋势反转
  • ​​山寨币退潮​​:Coinmarketcap山寨币季节指数回落至45,较8月11日的29略有回升,但远未达到“山寨季”门槛。数据显示市值前100加密货币中仅45个项目在90天内涨幅超越比特币,反映市场风险偏好的系统性收缩

市场波动率曲面揭示短期焦虑:以太坊7日隐含波动率升至73%,而30日IV保持在55%,显示投资者对杰克逊霍尔会议结果的紧张预期。

浴火重生:压力测试后的价值重构

杰克逊霍尔

尽管短期阴云密布,专业机构对以太坊的长期承载力保持审慎乐观。B2 Ventures创始人Arthur Azizov预判价格将在3,900-4,400美元区间盘整,等待“美联储政策转向和科技股表现”的明朗化。


HashKey的徐翰更强调市场吸收40亿美元抛压的能力:“来自机构ETF和数字资产库的强劲流入构成缓冲池”。


笔者预计以太坊在短期内或将再次测试120日均线即4070美金附近,甚至有可能触及斐波拉契0.618回撤即3926美金。


​​多空博弈的天平取决于两大转折点​​:

  • ​​技术升级进程​​:预计10月实施的EIP-4844升级将使Layer2交易成本降低90%,有望激活生态活力。若成功实施,生态复苏可能抵消质押收益劣势
  • ​​政策转向时机​​:当前CME FedWatch工具显示9月降息概率仍达82%。若杰克逊霍尔释放鸽派信号,配合通胀数据降温,风险资产或重获上涨动能

结语


当最后一批杠杆多头在4.51亿美元的爆仓烟火中倒下,加密市场完成了一场残酷的压力测试。40亿美元质押解锁与杰克逊霍尔会议构成双重时空裂缝,而裂缝深处,以太坊正经历从投机燃料向机构资产的痛苦蜕变。

Trending Cryptos

Related Reads

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit33m ago

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit33m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit33m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit33m ago

Trading

Spot

Hot Articles

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of ETH (ETH) are presented below.

活动图片